Developed by Eli Lilly and Incyte, rheumatoid arthritis drug baricitinib suffered a setback as an advisory committee to the U.S. Food and Drug Administration voted against approval of a 4-milligram dose. The committee did however vote in favor of approving a lower, 2 milligram (mg) dose.
The vote came a year after baricitinib was already rejected by the FDA, citing safety concerns.
Read the Retuers report